Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “ClearPoint is a company that provides both hardware and consumables to allow for the precise delivery of drugs to the brain and spine, with a particular focus on cell and gene therapies. The company offers both navigation systems (hardware) and a variety of accessories (consumables). Because its technologies are critical to various cell and gene therapies, they are initially used in clinical trials and eventually become an integral component to the delivery of these drugs when and if they are approved by FDA. This creates a long-term growth opportunity, characterized by high switching costs on a variety of recurring revenue streams. In many ways, ClearPoint is emblematic of many of our current holdings in the healthcare space, which are characterized by strong business models, high growth potential, and substantial embedded optionality, but have fallen very much out of favor relative to high-growth stocks in other sectors during the current healthcare sector downturn. In the case of ClearPoint, some of that optionality began to pay off this quarter because uniQure (QURE), one of ClearPoint's partners, reported excellent clinical data for its Huntington's Disease drug, which dramatically increased the odds of its eventual approval and reimbursement. If approved, this drug will have a profound impact on patients and provide a meaningful revenue stream to ClearPoint. It also serves as a proof point and source of optimism for other neurological cell and gene therapies that have integrated ClearPoint protocols into their therapies. We owned ClearPoint going into the uniQure news and continue to hold a position, as it remains a strong platform going forward with large growth prospects. Though no longer optically cheap, the valuation is reasonable if the company's pipeline continues to come to fruition and its installed base of hardware continues to expand. In addition, the market cap has now moved from well below $500M to over $800M, which brings shares of ClearPoint onto the radar of larger institutional small-cap funds, of which few seemed to own any stock prior to this recent move. This fits the paradigm of our core holdings that are ejecting out of micro-cap into what we would call the small-cap sweet spot. BSD Analysis: ClearPoint is carving out a real niche in MRI-guided neurosurgery, giving it a strong foothold in a highly specialized, high-margin medical workflow. Recurring disposables and service revenue provide long-term stability as the installed base grows. Adoption is slow but steady — typical for neurosurgical tech — and hospital stickiness is strong once integrated. Financials are still choppy, but the underlying business is moving in the right direction. The market prices CLPT as if it's stalled, but clinical value and procedural momentum keep improving. Execution matters, but the technology moat is real. A small but compelling med-tech compounder in the making.” | BULL | Q3 2025 Oct 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
